Bio-Rad Laboratories Q3 2024 Adj. EPS $2.01 Beats $1.16 Estimate, Sales $649.729M Beat $628.174M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bio-Rad Laboratories reported Q3 2024 earnings per share of $2.01, significantly surpassing the analyst estimate of $1.16. The company's sales also exceeded expectations, reaching $649.729 million compared to the estimated $628.174 million.

October 30, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bio-Rad Laboratories reported strong Q3 2024 results, with EPS of $2.01 beating estimates by 73.28% and sales of $649.729M surpassing expectations by 3.43%.
The significant beat on both EPS and sales indicates strong financial performance, likely leading to positive investor sentiment and a potential short-term increase in stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100